---
title: "Vysali Pharmaceuticals Ltd (524290) — Share Price, Financials & Analysis"
symbol: "524290"
company: "Vysali Pharmaceuticals Ltd"
canonical: "https://tapetide.com/stocks/524290"
isin: "INE153G01016"
bse_code: "524290"
sector: "Healthcare"
industry: "Pharmaceuticals & Biotechnology"
generated_at: "2026-09-13T18:47:58.992Z"
---

# Vysali Pharmaceuticals Ltd (524290)

Canonical page: https://tapetide.com/stocks/524290

## Company

- **BSE Code:** 524290
- **ISIN:** INE153G01016
- **Sector:** Healthcare
- **Industry:** Pharmaceuticals & Biotechnology
- **Macro Sector:** Healthcare
- **Stock Type:** EQUITY
- **Face Value:** ₹10
- **F&O Eligible:** No

## Latest Price

## Key Insights

### Strengths

- Company has reduced debt.
- Company's working capital requirements have reduced from 205 days to 147 days

### Weaknesses

- Company has low interest coverage ratio.
- Company might be capitalizing the interest cost

## Growth Rates

| Metric | 1Y |
| --- | --- |
| net income growth | 88% |
| revenue growth | 96% |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Sep 2024 | Mar 2025 | Sep 2025 |
| --- | --- | --- | --- |
| Sales | 36 | 32 | 37 |
| Expenses | 29 | 25 | 30 |
| Operating Profit | 7 | 7 | 7 |
| OPM % | 19 | 21 | 20 |
| Other Income | 1 | 1 | 2 |
| Interest | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 |
| Profit before tax | 8 | 8 | 9 |
| Tax % | 20 | 25 | 19 |
| Net Profit | 6 | 6 | 7 |
| EPS in Rs | 6.87 | 6.37 | 7.93 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2006 | Jun 2007 15m |
| --- | --- | --- |
| Sales | 5 | 10 |
| Expenses | 10 | 23 |
| Operating Profit | -5 | -13 |
| OPM % | -104 | -134 |
| Other Income | 1 | 26 |
| Interest | 0 | 0 |
| Depreciation | 0 | 0 |
| Profit before tax | -5 | 12 |
| Tax % | 0 | 0 |
| Net Profit | -5 | 12 |
| Dividend Payout % | 0 | 0 |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2006 | Jun 2007 |
| --- | --- | --- |
| Equity Capital | 5 | 5 |
| Reserves | -19 | 6 |
| Borrowings | 21 | 10 |
| Other Liabilities | 5 | 5 |
| Total Liabilities | 12 | 27 |
| Fixed Assets | 4 | 17 |
| CWIP | 0 | 0 |
| Investments | 0 | 0 |
| Other Assets | 8 | 10 |
| Total Assets | 12 | 27 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2006 | Jun 2007 |
| --- | --- | --- |
| Cash from Operating Activity | — | 12 |
| Cash from Investing Activity | — | 0 |
| Cash from Financing Activity | — | -11 |
| Net Cash Flow | — | 1 |
| Free Cash Flow | — | 12 |
| CFO/OP | — | -93 |

### Ratios

| Item | Mar 2006 | Jun 2007 |
| --- | --- | --- |
| Debtor Days | 62 | 71 |
| Inventory Days | 565 | 377 |
| Days Payable | 130 | 108 |
| Cash Conversion Cycle | 497 | 340 |
| Working Capital Days | 263 | 147 |
| ROCE % | — | -2 |

## Shareholding Pattern

### annual

| Category | Mar 2024 | Mar 2025 | Sep 2025 |
| --- | --- | --- | --- |
| Promoters | 73.66% | 73.72% | 73.72% |
| FIIs | 2.48% | 0% | 0% |
| DIIs | 2.17% | 0.4% | 0.4% |
| Public | 21.7% | 25.88% | 25.88% |
| No. of Shareholders | 1291 | 1619 | 1577 |

### Quarterly

| Category | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 |
| --- | --- | --- | --- | --- |
| Promoters | 73.66% | 73.66% | 73.72% | 73.72% |
| FIIs | 2.48% | 0% | 0% | 0% |
| DIIs | 2.17% | 0.4% | 0.4% | 0.4% |
| Public | 21.7% | 25.95% | 25.88% | 25.88% |
| No. of Shareholders | 1291 | 1684 | 1619 | 1577 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Strong Sell
- **Buy / Neutral / Sell:** 3 / 5 / 11

### Moving Averages — summary: **Strong Sell**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 318.42 | Sell |
| EMA (10) | 319.23 | Sell |
| SMA (20) | 323.88 | Sell |
| EMA (20) | 326.08 | Sell |
| SMA (50) | 353.88 | Sell |
| EMA (50) | 346.18 | Sell |
| SMA (100) | 379.04 | Sell |
| EMA (100) | 365.5 | Sell |
| SMA (200) | 393.67 | Sell |
| EMA (200) | 378.88 | Sell |

### Oscillators — summary: **Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 41.85 | Neutral |
| MACD (12,26,9) | -10 | Buy |
| Stochastic (14,3,3) | 19.39 | Buy |
| ADX (14) | 7.53 | Neutral |
| Williams %R (14) | -80.73 | Buy |
| ATR (14) | 16.43 | High Volatility |
| ROC (12) | -3.76 | Sell |
| Stoch RSI (14) | 38.13 | Neutral |
| UO (7,14,28) | 32.91 | Neutral |

## Filings & Documents

### Other Documents

| Date | Document |
| --- | --- |
| 9 February 2026 - Appointed Ravichandra Rangu as Consultant, Associate Head of Sales – APAC, effective February 09, 2026. | [General Updates 9 February 2026 - Appointed Ravichandra Rangu as Consultant, Associate Head of Sales – APAC, effective February 09, 2026.](https://nsearchives.nseindia.com/corporate/DELAPLEX_09022026181146_Intimation_Appointment_of_Consultant_Signed.pdf) |
| 4 February 2026 - Revised SEBI-formatted audited standalone and consolidated results for year ended 31 Mar 2025; consolidated PAT Rs1,220.33 lakh. | [Reply to Clarification- Financial results 4 February 2026 - Revised SEBI-formatted audited standalone and consolidated results for year ended 31 Mar 2025; consolidated PAT Rs1,220.33 lakh.](https://nsearchives.nseindia.com/corporate/DELAPLEX_04072025194828_Financial_Results_signed.pdf) |
| 4 February 2026 - Feb 3, 2026: Delaplex praises Budget 2026 (tax holiday to 2047), cites BSNL MDC MOU, edge focus. | [Press Release 4 February 2026 - Feb 3, 2026: Delaplex praises Budget 2026 (tax holiday to 2047), cites BSNL MDC MOU, edge focus.](https://nsearchives.nseindia.com/corporate/DELAPLEX_04022026123459_Media_Release_Budget_2026_Signed.pdf) |
| 20 January 2026 - Reg 74(5) certificate: all shares dematerialised; no rematerialisation requests for quarter ended 31 Dec 2025. | [Certificate under SEBI (Depositories and Participants) Regulations, 2018 20 January 2026 - Reg 74(5) certificate: all shares dematerialised; no rematerialisation requests for quarter ended 31 Dec 2025.](https://nsearchives.nseindia.com/corporate/DELAPLEX_20012026180101_Reg_74_5__Signed.pdf) |
| 20 January 2026 - Delaplex Limited has informed regarding Non-applicability of the compliance on Corporate Governance for the Quater ended 31st December, 2025. | [Quarterly Compliance Report on Corporate governance - within 21 days from the end of the quarter 20 January 2026 - Delaplex Limited has informed regarding Non-applicability of the compliance on Corporate Governance for the Quater ended 31st December, 2025.](https://nsearchives.nseindia.com/corporate/DELAPLEX_20012026175313_Corporate_Governance_Signed.pdf) |
| 10 March 2026 - Promoter MD Nitin Sachdeva acquired 7,800 shares (0.086%) on 10-Mar-2026 via open market. | [Updates 10 March 2026 - Promoter MD Nitin Sachdeva acquired 7,800 shares (0.086%) on 10-Mar-2026 via open market.](https://nsearchives.nseindia.com/corporate/DELAPLEX_10032026172842_Intimation_under_regulatiion_29_of_SAST_Final_Signed.pdf) |

### Earnings Call Documents

| Date | Document |
| --- | --- |
| Nov 2025 | [Concall - Nov 2025](https://nsearchives.nseindia.com/corporate/DELAPLEX_24112025191130_Transcript_signed.pdf) |
| Nov 2024 | [Concall - Nov 2024](https://nsearchives.nseindia.com/corporate/DELAPLEX_15112024164045_Intimation_to_NSE_Investor_PPT.pdf) |
| Jun 2024 | [Concall - Jun 2024](https://nsearchives.nseindia.com/corporate/DELAPLEX_22062024193209_dPInvestorDeck062224.pdf) |

### Annual Reports

| Date | Document |
| --- | --- |
| from nse | [Financial Year 2025 from nse](https://archives.nseindia.com/annual_reports/SME_AR_27267_DELAPLEX_2024_2025_A_04082025181507.pdf) |
| from nse | [Financial Year 2024 from nse](https://archives.nseindia.com/annual_reports/SME_AR_24931_DELAPLEX_2023_2024_1308202419337.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T18:47:58.992Z.